SCHEMBL31326337

SCHEMBL31326337

N#Cc1cnc2[nH]cc(CCNCc3ccccc3F)c2c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HTR2A P28223 2/20 0.47
▸ MPO P05164 3/20 0.44
▸ CHEK1 O14757 1/20 0.43
▸ CYP3A4 P08684 4/20 0.43
▸ CYP2D6 P10635 4/20 0.43
▸ CYP1A2 P05177 3/20 0.43
▸ CYP2C19 P33261 3/20 0.43
▸ MAPT P10636 2/20 0.43
▸ KMT2A Q03164 2/20 0.43
▸ HTR1A P08908 1/20 0.43
▸ DRD2 P14416 1/20 0.43
▸ HTR7 P34969 1/20 0.43
▸ HTR6 P50406 1/20 0.43
▸ LMNA P02545 1/20 0.43
▸ HTT P42858 1/20 0.43
▸ SMN1; SMN2 Q16637 1/20 0.43
▸ HPGD P15428 1/20 0.43
▸ MC5R P33032 1/20 0.41
▸ MC3R P41968 1/20 0.41
▸ MC1R Q01726 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Fumaric Acid SCHEMBL31635984 0.92 CHEK1 (0.44) HTR2AMPOCHEK1CYP3A4CYP2D6
SCHEMBL31326349 0.85 CYP3A4 (0.56) HTR2AMPOCYP3A4CYP2D6CYP1A2
SCHEMBL31326330 0.84 HTR2A (0.54) HTR2AMPOCHEK1CYP3A4CYP2D6
SCHEMBL31326343 0.83 MPO (0.47) HTR2AMPOCYP3A4CYP2D6CYP1A2
SCHEMBL31326334 0.83 HTR6 (0.49) HTR2AMPOCHEK1CYP3A4CYP2D6
SCHEMBL1267858 0.78 CYP3A4 (0.55) CYP3A4CYP2D6CYP2C19HTR1ACYP2C9
Fumaric Acid SCHEMBL31636020 0.77 HTR2A (0.47) HTR2AMPOCHEK1CYP3A4CYP2D6
SCHEMBL31326352 0.76 KMT2A (0.60) HTR2ACHEK1CYP3A4CYP2D6CYP1A2
Fumaric Acid SCHEMBL31635950 0.76 HTR6 (0.56) HTR2AMPOCHEK1CYP3A4CYP2D6
SCHEMBL31635985 0.73 AAK1 (0.37) CYP3A4CYP2D6CYP1A2CYP2C19KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4735441-A1 PYRROLOPYRIDINE COMPOUNDS FOR THE TREATMENT OF MENTAL ILLNESSES Psylo Pty Ltd (AU) 2026-05-06 — — EP disclosed
US-20250361233-A1 Compounds For Activating Serotonin Receptor Psylo Pty Ltd (AU) 2025-11-27 — — US disclosed
US-12415804-B2 Compounds for activating a serotonin receptor Psylo Pty Ltd (AU) 2025-09-16 — — US disclosed
US-20250206739-A1 Compounds Psylo Pty Ltd (AU) 2025-06-26 — — US disclosed
WO-2025000051-A1 PYRROLOPYRIDINE COMPOUNDS FOR THE TREATMENT OF MENTAL ILLNESSES Psylo Pty Ltd (AU) 2025-01-02 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250206739-A1 Compounds NLN, SLC18A2, PYGB HTR2A 94/4885MPO 559/4885CHEK1 2942/4885
US-12415804-B2 Compounds for activating a serotonin receptor HTR2C, HTR6, HTR2A HTR2A 3/4885MPO 2816/4885CHEK1 2108/4885
US-20250361233-A1 Compounds For Activating Serotonin Receptor HTR2C, HTR2A, HTR6 HTR2A 2/4885MPO 3106/4885CHEK1 2277/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback